
    
      This study is a prospective, non-randomized, single-arm, multi-center condition of approval
      evaluation. The device is currently FDA approved for commercial distribution. Subjects with
      ischemic ventricular tachycardia will be considered for the condition of approval study. This
      study will be conducted at up to 30 centers in a minimum of 249 evaluable subjects.
    
  